George Kontopidis

Prof. George Kontopidis

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Protein Expression and Purification
Verified
Journal Article
Closed access
Christos PapaneophytouChristos Papaneophytou
Christos Papaneophytou
GKGeorge Kontopidis
George Kontopidis

14 July 2014 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
Christos PapaneophytouChristos Papaneophytou
Christos Papaneophytou
AGAsterios I. Grigoroudis
Asterios I. Grigoroudis
CMCampbell McInnes
Campbell McInnes
GKGeorge Kontopidis
George Kontopidis
In order to quantify the interactions between molecules of biological interest, the determination of the dissociation constant (Kd) is essential. Estimation of the binding affinity in this way is routinely performed in “favorable” conditions for macromolecules. Crucial data for ligand–protein binding elucidation is mainly derived from techniques (e.g., macromolecular crystallography) that require the addition of high concentration of salts and/or other additives. In this study we have evaluated the effect of temperature, ionic strength, viscosity, and hydrophobicity on the Kd of three previously characterized protein–ligand systems, based on variation in their binding sites, in order to provide insight into how these often overlooked unconventional circumstances impact binding affinity. Our conclusions are as follows: (1) increasing solvent viscosity in general is detrimental to ligand binding, (2) moderate increases in temperature have marginal effects on the dissociation constant, and (3) the degree of hydrophobicity of the ligand and the binding site determines the extent of the influence of cosolvents and salt concentration on ligand binding affinity.

6 September 2018 in Journal of Liposome Research
Verified
Journal Article
Closed access
MRMagdalini Rovoli
Magdalini Rovoli
IPIoannis Pappas
Ioannis Pappas
Stavros I. LalasStavros I. Lalas
Stavros I. Lalas
OGOlga Gortzi
Olga Gortzi
GKGeorge Kontopidis
George Kontopidis
Vitamin A (VA) is an essential nutrient needed in small amounts by humans and supports a wide range of biological actions. Retinol, the most common and most biologically active form of VA has also been found to inhibit peroxidation processes in membranes and it has been widely used as an ingredient with pharmaceutical and nutritional applications. VA is a lipophilic molecule, sensitive to air, oxidizing agents, ultraviolet light and low pH levels. For these reasons, it is necessary for VA to be protected against oxidation. Another disadvantage in the application of VA is its low solubility in aqueous media. Both issues (sensitivity and solubility) can be solved by employing encapsulation techniques. Liposomes can efficiently encapsulate lipid-soluble materials, such as VA. The encapsulated materials are protected from environmental and chemical changes. A new liposome/β-lactoglobulin formulation has been developed as a stable delivery system for VA. The aim of this study was the encapsulation of VA into β-lactoglobulin–liposome complexes, recently developed in our laboratory. The in vivo bioavailability characterization of VA was tested after administration in laboratory animals (mice). In this report, we demonstrate that VA could be efficiently entrapped and delivered in a phospholipid–sterol–protein membrane resembling system, a newly synthesized promising carrier. Based on this finding, the phospholipid–sterol–protein membrane resembling system may be one of the promising approaches to enhance VA absorption and to overcome the formulation difficulties associated with lipophilic means. The carrier system described here has huge potential in food fortification applications to treat VA deficiency.

4 December 2012 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Christos PapaneophytouChristos Papaneophytou
Christos Papaneophytou
AMAnthi K. Mettou
Anthi K. Mettou
VRVagelis Rinotas
Vagelis Rinotas
Eleni K. DouniEleni K. Douni
Eleni K. Douni
GKGeorge Kontopidis
George Kontopidis

1 April 2016 in Protein Expression and Purification
Verified
Journal Article
Closed access
Christos PapaneophytouChristos Papaneophytou
Christos Papaneophytou
GKGeorge Kontopidis
George Kontopidis

19 May 2015 in MedChemComm
Verified
Journal Article
Closed access
PDF file
Christos PapaneophytouChristos Papaneophytou
Christos Papaneophytou
PAPolyxeni Alexiou
Polyxeni Alexiou
Athanasios PapakyriakouAthanasios Papakyriakou
Athanasios Papakyriakou
ENEvangelos Ntougkos
Evangelos Ntougkos
KTKaterina Tsiliouka
Katerina Tsiliouka
GKGeorge Kontopidis
George Kontopidis
Inhibition of tumor necrosis factor (TNF) production or function by small molecules has become a major focus in the pharmaceutical industry for the treatment of rheumatoid arthritis. In this study, a series of 39 novel SPD-304 analogs were designed, synthesized and evaluated as TNF inhibitors. Our results show that small structural changes produce ligands with similar binding affinities (Kd) for TNF, but significantly different potencies in a L929 cell-based assay. In addition, contrary to the high affinity of compounds 4e, 8c and 10e for TNF in vitro, the potency of these compounds was determined to be low. We propose that these differences can partly be explained by the physicochemical characteristics of the synthesized SPD-304 analogs. Our findings were supplemented by molecular docking studies on the TNF dimer. These synthesized analogs may serve as a starting point for developing novel TNF inhibitors.